MC4R raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-22 and is reviewed periodically as new material appears.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
=== In humans === Xylazine is absorbed, metabolized, and eliminated rapidly. It can be inhaled or administered intravenously, intramuscularly, subcutaneously, or orally either by itself or in conjunction with other anesthetics, such as ketamine, barbiturates, chloral hydrate, and halothane in order to provide reliable anesthesia effects. The most common route of administration is injection. Xylazine's action can be seen usually 15–30 minutes after administration and the sedative effect may continue for 1–2 hours and last up to 4 hours. Once xylazine gains access to the vascular system, it is distributed within the blood, allowing it to enter the heart, lungs, liver, and kidneys. In non-fatal cases, the blood plasma concentrations range from 0.03 to 4.6 mg/L. Xylazine diffuses extensively and penetrates the blood–brain barrier, since the molecule does not have a charge and dissolves in lipids. Xylazine is metabolized by the liver's cytochrome P450 enzymes. When it reaches the liver, xylazine is metabolized and proceeds to the kidneys to be excreted in urine. Around 70% of a dose is excreted unchanged. Thus, urine can be used in detecting xylazine administration because it contains many metabolites, which are the main targets and products in urine. Within a few hours, xylazine decreases to undetectable levels. Other factors can also significantly impact the pharmacokinetics of xylazine, such as sex, nutrition, environmental conditions, and prior diseases.
== External links == ENZYME — Expasy enzyme nomenclature database ENZO — Web application for easy construction and quick testing of kinetic models of enzyme catalyzed reactions. ExCatDB — A database of enzyme catalytic mechanisms BRENDA — Comprehensive enzyme database, giving substrates, inhibitors and reaction diagrams
Deman acknowledges that Wolverine is a gruff loner who often takes leave from the X-Men to deal with personal issues or problems, irreverent and rebellious towards authority figures, and displays a wry, sarcastic sense of humor. Despite this, Deman also notes that Wolverine is a reliable ally and competent leader, as well as capable of warmth, compassion, and empathy. Clinical psychologist and Navy veteran Larry Yarbrough recognizes that while "Logan has an extremely reactive temper" he is "also a kind person", pointing out that the "violent/kind demeanor" he displays is typical of combat veterans. According to him, Wolverine's "violent mood swings are a symptom of trauma, not a reflection of his character". He also observes Wolverine's habitual smoking and drinking, which are coping mechanisms for his traumatic experiences. Psychologist Suzana E. Flores writes that Wolverine demonstrates clinical psychological symptoms of post-traumatic stress disorder, bipolar disorder, antisocial personality disorder, dissociative disorder, and even sociopathy, but does so in a way that can be understood and empathized. She interprets his origin story as a depiction of complex childhood trauma, and its effects of dissociative amnesia and hypervigilance. She argues that his first formative trauma was his poor relationship with his mother, who was unable to properly attach to him because she lost her first son. In adulthood, he also suffered the trauma of torture by the Weapon X program.
Sources: en.wikipedia.org
Examples of China's increasing global presence as an arms supplier in 2010–14 included deals with Venezuela for armoured vehicles and transport and trainer aircraft, with Algeria for three frigates, with Indonesia for the supply of hundreds of anti-ship missiles and with Nigeria for the supply of several unmanned combat aerial vehicles. Following rapid advances in its arms industry, China has become less dependent on arms imports, which decreased by 42 percent between 2005–09 and 2010–14. Russia accounted for 61 percent of Chinese arms imports, followed by France with 16 percent and Ukraine with 13 per cent. Helicopters formed a major part of Russian and French deliveries, with the French designs produced under licence in China. From 2021 to 2026, China's arms imports fell by 72 percent; Russia accounted for 66 percent of China's arms imports. Over the years, China has struggled to design and produce effective engines for combat and transport vehicles. It continued to import large numbers of engines from Russia and Ukraine in 2010–14 for indigenously designed combat, advanced trainer and transport aircraft, and naval ships. It also produced British-, French- and German-designed engines for combat aircraft, naval ships and armoured vehicles, mostly as part of agreements that have been in place for decades. In August 2021, China tested a nuclear-capable hypersonic missile that circled the globe before speeding towards its target.
There are over 800 extant species of cephalopod, although new species continue to be described. An estimated 11,000 extinct taxa have been described, although the soft-bodied nature of cephalopods means they are not easily fossilised. Cephalopods are found in all the oceans of Earth. None of them can tolerate fresh water, but the brief squid, Lolliguncula brevis, found in the Chesapeake Bay, is a notable partial exception in that it tolerates brackish water. Cephalopods are thought to be unable to live in fresh water due to multiple biochemical constraints, and in their >400 million year existence have never ventured into fully freshwater habitats. Cephalopods occupy most of the depth of the ocean, from the abyssal plains to the sea surface, and have also been found in the hadal zone. Their diversity is greatest near the equator (~40 species retrieved in nets at 11°N by a diversity study) and decreases towards the poles (~5 species captured at 60°N).
If a stepparent legally adopts the partner's child or children, he or she becomes the child's legal parent. In such cases, the parents may stop using the terms stepparent and stepchild and instead refer to the child simply as their son or daughter; depending on the child's degree of affinity for the adoptive parent and/or approval of the legal proceedings culminating in the child's adoption, the child may likewise drop the "step-" designation from his or her description of the relationship. Even when all parties describe the relationship using the terms applied to biological and adoptive families, however, at least some of the emotional and psychological issues common to stepfamilies may or may not persist. Thus, one possibility is that a stepfamily can be reconfigured, and thanks to the biological and adoptive links could leave the condition of a stepfamily.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.